摘要
目的观察瑞舒伐他汀与阿托伐他汀对冠心病患者经皮冠状动脉介入(PCI)术后血脂、同型半胱胺酸水平的影响。方法回顾性分析2018年3月至9月在浙江省人民医院行PCI治疗的冠心病患者145例,分为瑞舒伐他汀组和阿托伐他汀组。比较两组患者治疗前,治疗1、12个月血清胆固醇和同型半胱胺酸水平、主要心血管不良事件(MACE)发生情况。结果两组患者与治疗前比较,治疗1、12个月低密度脂蛋白胆固醇(LDL-C)水平下降,高密度脂蛋白胆固醇(HDL-C)水平升高,差异均有统计学意义(均P<0.05);与阿托伐他汀组相比,瑞舒伐他汀组患者LDL-C水平下降、HDL水平升高,差异均有统计学意义(均P<0.05)。治疗12个月两组患者LDL-C水平较治疗1个月有所上升(均P<0.05),但仍低于治疗前(均P<0.05)。治疗12个月两组患者同型半胱胺酸水平较治疗前有明显下降,差异均有统计学意义(均P<0.05)。两组患者随访期间MACE发生率差异无统计学意义(P>0.05)。结论瑞舒伐他汀较阿托伐他汀降低LDL-C和升高HDL-C的作用更强,两者均能够同等程度降低同型半胱氨酸。
Objective To compare the effects of rosuvastatin and atorvastatin on blood lipid and homocysteine of patients with coronary heart disease(CAD)after percutaneous coronary intervention(PCI).Methods The data of 145 CAD patients underwent PCI in Zhejiang Provincial People's Hospital from March to September 2018 were analyzed retrospectively.They were divided into rosuvastatin group and atorvastatin group.The blood lipid and homocysteine before the treatment,1 and 12 months later after treatment,and major cardiovascular adverse events during follow-up were compared between the two groups.Results LDL-C decreased and HDL-C increased significantly after 1 and 12 months in both of the two groups(all P<0.05).Compared with atorvastatin group,LDL-C was significantly lower and HDL was significantly higher in rosuvastatin group(all P<0.05).LDL-C was significantly higher at the12th month than at the first month(all P<0.05),but was still lower than the baseline value before treatment(all P<0.05).The level of homocysteine after 12-month treatment was significantly lower than that before treatment(all P<0.05).The incidence of major adverse cardiovascular events was similar in the two groups during follow-up(P>0.05).Conclusion Rosuvastatin is more effective in reducing LDL-C and increasing HDL-C than atorvastatin.Both atorvastatin and rosuvastatin can slowly reduce homocysteine.
作者
郑小春
林敬阳
ZHENG Xiaochun;LIN Jingyang(Department of Pharmacy,Zhejiang Provincial People's Hospital,Peple's Hospital of Hangzhou Medical College,Hangzhou 310014,China)
出处
《心电与循环》
2020年第4期357-359,368,共4页
Journal of Electrocardiology and Circulation
基金
浙江省中医药科技计划(2015ZQ005,2018ZB021,2019ZB009)
浙江医药卫生科技计划(2019KY276)。
关键词
瑞舒伐他汀
阿托伐他汀
经皮冠状动脉介入
冠心病
Rosuvastatin
Atorvastatin
Percutaneous coronary intervention
Coronary artery disease
